



# SUVEN Life Sciences

## Communication to investors Mar 2013

14-May-13

*2012-13 Q4 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

# FINANCIAL QUICK VIEW

## Quarter 4 – Mar 2013



# FINANCIAL QUICK VIEW

## Year ending – Mar 2013



# MAJOR PROFITABILITY RATIOS




	Q4 Mar 13	YE Mar 13
PAT to Income	11.47%	11.91%
EBIDTA to Income	18.79%	20.94%
Cash Flow to Income	14.32%	14.95%
Pre-R&D EBITDA to Income	31.84%	34.34%

14-May-13

2012-13 Q4 results



# INCOME COMPARISON




14-May-13

2012-13 Q4 results



# PROFIT COMPARISON




14-May-13

2012-13 Q4 results



# EBIDTA COMPARISON




14-May-13

2012-13 Q4 results






# R & D – EXPENDITURE



14-May-13

2012-13 Q4 results

# PRE-R&D EBIDTA




14-May-13

2012-13 Q4 results



# PRE-R&D CASHFLOW



14-May-13

2012-13 Q4 results



# Updates for the quarter

- Suven's drug discovery pipeline consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
- The Board has recommended a Dividend of Re 0.30 per share (30% of face value of Rs.1.00 each) for the accounting year 2012-13 subject to the approval in AGM